INAB Stock Analysis: Buy, Sell, or Hold?
INAB - IN8bio, Inc. Common Stock
$0.96
-0.07 (-7.25%)
▼
5d:
-19.33%
30d:
-32.39%
90d:
-36.0%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
2d
Get Alerted When INAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: INAB is down 19.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: INAB is down 19.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: INAB is currently trading at $0.96, which is considered oversold relative to its 30-day fair value range of $1.15 to $1.43.
Technical Outlook: Technically, INAB is in a downtrend. The price is currently testing key support at $0.94. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.25 (+551.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INAB is in a downtrend. The price is currently testing key support at $0.94. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.25 (+551.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.15 -
$1.43
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.2%)
- BULLISH: Trading 551.0% below Wall St target ($6.25)
- WARNING: Recommendation downgraded due to -19.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.15 -
$1.43
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.94
Resistance Level
$1.25
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.91
Wall Street Target
$6.25
(+551.0%)
Share & Embed Analysis
Last updated: August 03, 2026 6:32 PM ET
Data refreshes hourly during market hours. Next update: 7:32 PM
Data refreshes hourly during market hours. Next update: 7:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
